Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 27 |
| Active Pipeline (Recruiting Now) | 3 (3) |
| Completed vs Stopped Early | 15 / 0 (0.0%) |
| Median Closed Actual Enrollment | 172 participants |
| Physical Hospital Site Disclosure | 91.8% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Seoul National University Hospital | Seoul | 6 |
| Korea University Guro Hospital | Seoul | 5 |
| The Catholic University of Korea, Seoul St. Mary's Hospital | Seoul | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03726853 | The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497 | Phase II | COMPLETED |
| NCT03437785 | Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet | Phase II | COMPLETED |
| NCT04255589 | A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Chong Kun Dang Pharmaceutical Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.